NEW DELHI: According to data from the Union health ministry updated on Thursday, 3,016 new COVID cases were reported in India in the past 24 hours, an increase of almost 40% from the daily total.
The number of active cases has increased to 13,509, which is the largest daily COVID case count seen in almost six months. On October 2 of the previous year, there were a total of 3,375 instances. The number of COVID-related deaths in India has risen to 5,30,862 with the addition of 14 new fatalities, including eight resolved by Kerala and three each from Maharashtra, Delhi, and Himachal State within a 24-hour period.
After 300 new instances of COVID-19 were reported in the nation's capital on Wednesday, Saurabh Bhardwaj, the minister of health for Delhi, summoned an urgent meeting today.
According to Bhardwaj, Arvind Kejriwal, the chief minister of Delhi, gave the order to conduct the emergency meeting at noon in light of the rise in COVID cases in the city. "There is now no discussion of such limits," he continued. Weekly positivity was estimated to be 1.71 percent, whereas the daily positivity was 2.73 percent.
According to the health ministry website, the infection count has reached 4,471,296; the active caseload now represents 0.03 percent of the total cases, and the recovery rate is 98.78 percent. 4,416,827 persons have recovered from the illness, and the case fatality rate has been reported at 1.19 percent.
As part of the statewide immunisation campaign, approximately 220.65 crore doses of the Covid vaccine have so far been given out in the nation.
In a related development, the discovery of a small molecule that makes the COVID-19 causing virus SARS-CoV-2 ineffective, is expected to provide a new basis for medication to shorten the course of the virus after exposure to it, a new study has revealed.
Researchers from the University of Houston (UH) in the US, said that the molecule could provide immediate protection against viral infection for high-risk and immune-compromised individuals who typically do not generate sufficient antibodies after vaccination and thus, may be suitable for people across age groups.
Also Watch: